UCSF-UC Berkeley Joint PhD Program in Bioengineering , San Francisco, California 94143, United States.
ACS Nano. 2017 Aug 22;11(8):7747-7757. doi: 10.1021/acsnano.7b01239. Epub 2017 Aug 7.
Encapsulation of human embryonic stem-cell-differentiated beta cell clusters (hES-βC) holds great promise for cell replacement therapy for the treatment of diabetics without the need for chronic systemic immune suppression. Here, we demonstrate a nanoporous immunoprotective polymer thin film cell encapsulation device that can exclude immune molecules while allowing exchange of oxygen and nutrients necessary for in vitro and in vivo stem cell viability and function. Biocompatibility studies show the device promotes neovascular formation with limited foreign body response in vivo. The device also successfully prevented teratoma escape into the peritoneal cavity of mice. Long-term animal studies demonstrate evidence of engraftment, viability, and function of cells encapsulated in the device after 6 months. Finally, in vivo study confirms that the device was able to effectively immuno-isolate cells from the host immune system.
人胚胎干细胞分化的β细胞簇（hES-βC）的封装为无需进行慢性系统性免疫抑制的糖尿病细胞替代疗法带来了巨大的希望。在这里，我们展示了一种纳米多孔免疫保护聚合物薄膜细胞封装装置，该装置可以排除免疫分子，同时允许体外和体内干细胞存活和功能所需的氧气和营养物质的交换。生物相容性研究表明，该装置在体内促进了新生血管形成，异物反应有限。该装置还成功地防止了畸胎瘤逃入小鼠的腹腔。长期动物研究表明，在 6 个月后，封装在该装置中的细胞有植入、存活和功能的证据。最后，体内研究证实该装置能够有效地将细胞与宿主免疫系统免疫隔离。
